P-081: Phase II

P-081 increased HDL (beneficial) cholesterol levels by 13.5 mg/dl (28.6 percent) over baseline in a Phase II study of 60 post-menopausal women in Australia who received the compound for 6 months. In addition, the ratio of HDL to LDL cholesterol improved by 21 percent in the patients. When patients were switched to placebo, cholesterol levels returned to baseline in 2 months. No adverse events were reported. ...